BioMarin Pharmaceutical Inc. (BMRN), Wednesday announced positive data from the CANOPY clinical program evaluating Voxzogo in children with achondroplasia, a rare genetic skeletal condition, and other similar conditions.
The results revealed that children with achondroplasia treated with the prescription medicine experienced meaningful improvements beyond height, such as in health-related quality of life, and increased bone length while maintaining bone strength.
Also, additional results from investigator-led study noted sustained growth gains in children with hypochondroplasia, noonan syndrome and genetic variants associated with idiopathic short stature.
Currently, BioMarin's stock is trading at $71.47, up 1.26 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.